Search

Your search keyword '"Hendriks, L."' showing total 721 results

Search Constraints

Start Over You searched for: Author "Hendriks, L." Remove constraint Author: "Hendriks, L."
721 results on '"Hendriks, L."'

Search Results

1. Technical Design Report for the LUXE experiment

2. Technical Design Report for the LUXE Experiment

Catalog

Books, media, physical & digital resources

3. The Dark Machines Anomaly Score Challenge: Benchmark Data and Model Independent Event Classification for the Large Hadron Collider

4. Les Houches 2019 Physics at TeV Colliders: New Physics Working Group Report

5. Combined asteroseismology, spectroscopy, and astrometry of the CoRoT B2V target HD 170580

10. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel

11. Process Mining for Detailed Process Analysis

12. The Dark Machines Anomaly Score Challenge: Benchmark Data and Model Independent Event Classification for the Large Hadron Collider

13. Towards a Framework in Interaction Training for Staff Working with Clients with Intellectual Disabilities and Challenging Behaviour

15. OC-0607 Pattern of brain metastases after HA-PCI and SRCF in SCLC: pooled findings of NCT01780675 and PREMER

17. Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

18. Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink Aurum and GOLD

21. Ik wil je iets vertellen: Over het belang voor jonge kinderen om te praten over nare ervaringen

22. Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink Aurum and GOLD

23. Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

24. Results of an interlaboratory comparison for characterization of Pt nanoparticles using single-particle ICP-TOFMS

26. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

27. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

28. Figure S1 from Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer

29. 4P FDG PET derived metabolic tumor volume (MTV) and its transcriptomic correlates as biomarker to predict efficacy of immune checkpoint inhibitors (ICB) alone or in combination with chemotherapy in advanced NSCLC: A multicentric study

35. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)

36. 27P Influence of single nucleotide polymorphisms (SNPs) in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

37. 957P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on toxicity and immune therapy

39. 1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels

40. Sexual Risk Assessment for People with Intellectual Disabilities

41. Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?

43. Cost-utility analysis of repetitive transcranial magnetic stimulation as add-on therapy to standard care for the treatment of hallucinations in schizophrenia

44. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)

45. Exercise in lung Cancer, the healthcare providers opinion (ECHO): Results of the EORTC lung cancer Group (LCG) survey

46. Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches

49. OC-0438 Proton-therapy and concurrent chemotherapy in stage III NSCLC: effects on hematological toxicity

50. 127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?